Sanofi Spends $1.4bn for Production of Insulin in Germany

Sanofi has revealed plans to invest a substantial €1.3 billion ($1.4 billion) in an enlarged plant located in Frankfurt, Germany, to enhance its insulin production capacity. When it opens in 2029, the 36,000 square foot facility will be located at Sanofi’s current BioCampus location.

Subject to clearance from the European Union, Sanofi will carry out the initiative with assistance from the state government of Hesse and the federal government of Germany.

Sanofi manufacturing and supply global head Brendan O’Callaghan commented: “With this project, we reaffirm our commitment to help diabetes sufferers around the world.

He continued: “We’re using the long-time expertise of our Frankfurt BioCampus and its highly qualified personnel.”

The investment follows the official pharma policy that the German government adopted in 2023 to increase assistance for pharmaceutical businesses. Additionally, the strategy improves the environment for national research and development while expediting approval procedures.

Sanofi Germany chairman Heidrun Irschik-Hadjieff stated: “Our planned investment underscores the central role played by the Frankfurt BioCampus in strengthening the resilience of global insulin production.

They continued: “The strong support of both the national and regional German governments is a powerful signal for the biopharmaceutical industry.”